CN Patent

CN115003667B — Tyk-2抑制剂

Assigned to Beone Pharmaceutical Suzhou Co Ltd · Expires 2025-04-15 · 1y expired

What this patent protects

本文披露了一种用于抑制TYK2和治疗与不希望的tyk‑2活性相关的疾病(tyk‑2相关疾病)的具有式(I)的化合物、一种使用本文披露的化合物治疗炎性疾病或自身免疫性疾病的方法、和一种包含该化合物的药物组合物。

USPTO Abstract

本文披露了一种用于抑制TYK2和治疗与不希望的tyk‑2活性相关的疾病(tyk‑2相关疾病)的具有式(I)的化合物、一种使用本文披露的化合物治疗炎性疾病或自身免疫性疾病的方法、和一种包含该化合物的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN115003667B
Jurisdiction
CN
Classification
—
Expires
2025-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Beone Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.